August, 2021

Tuesday, August 3rd, 2021

28-year-old Swedish electronic dance music artist Avicii dies in Oman

Monday, April 23, 2018

On Friday afternoon, Swedish electronic dance music artist Tim Bergling, stage name Avicii, was found dead in Oman’s capital Muscat, stated his publicist Diana Baron. Baron did not specify the cause of Bergling’s death in the statement and added, “the family is devastated and we ask everyone to please respect their need for privacy in this difficult time.” Bergling was 28 years old.

Born on September 8, 1989, in the Swedish capital Stockholm, Bergling released his first single in 2007. His single Levels, released in 2011, received a Grammy Award nomination. He released his debut album True in 2013; singles from True include Hey Brother and Wake Me Up. In October 2015, he released his second album Stories. Bergling has won American Music Awards, Billboard Music Awards and MTV Europe Music Awards. He received second Grammy nomination for Sunshine, which he collaborated with David Guetta.

In 2014, Bergling collaborated with Carlos Santana and Wyclef Jean to release We Will Find a Way, one of the anthems for that year’s FIFA Men’s football World Cup in Brazil. In March 2014, Bergling was hospitalised. He had surgery to remove his gall bladder and appendix that year, and had previously suffered from pancreatitis in 2012. He announced quitting touring in early 2016, after performing at the Ultra Music Festival.

Speaking to Billboard magazine, Bergling said he stopped touring for the health complications. He added, “The scene was not for me. It was not the shows and not the music. It was always the other stuff surrounding it that never came naturally to me […] I’m more of an introverted person in general. It was always very hard for me. I took on board too much negative energy, I think”.

In his twelve-year career, Bergling collaborated with Madonna, David Guetta, Jon Bon Jovi, Rita Ora, Coldplay, Aloe Blacc and Robbie Williams. Bergling had about eleven billion streams on music streaming platform Spotify. Bergling released his final EP called AV?CI (01) in 2017, which was nominated for a Billboard award recently.

In an interview with VEVO Lift, Bergling explained about his stage name saying, “the name Avici means the lowest level of Buddhist hell”. He said he added an extra ‘i’ since someone else was using that name on MySpace.

After Bergling’s death, pop singer Madonna tweeted, “So Sad……. So Tragic. Good Bye Dear Sweet Tim. ? Gone too Soon.”

Retrieved from “https://en.wikinews.org/w/index.php?title=28-year-old_Swedish_electronic_dance_music_artist_Avicii_dies_in_Oman&oldid=4506840”
Monday, August 2nd, 2021

MLB: Pirates complete sweep of Astros

Thursday, April 5, 2007

Pittsburgh Pirates 5 4 Houston Astros

The Pittsburgh Pirates swept the Houston Astros in a 5-4 victory at the Minute Maid Park Wednesday. Xavier Nady did very well in the first three games of the season, going 1 for 4 with 2 runs to lift the Pirates over the Astros. Tom Gorzelanny made his debut in the last game of the series, giving up 3 runs on 7 hits, with 2 errors, with one ball batted and four strikeouts. This is the first time since May 1991 that the Pirates swept the Astros.

Trailing by two runs in the fifth, Pittsburgh capitalized on three fielding errors to put them ahead by two. Craig Biggio hit a solo home run with two outs in the ninth inning, but Pittsburgh closer Salomon Torres struck out the last batter and picked up the save.

The Astros are off until Friday when the St. Louis Cardinals visit for three games. Meanwhile, the Pirates are concluding their opening road trip in Cincinnati before returning home to face the Cardinals.

Retrieved from “https://en.wikinews.org/w/index.php?title=MLB:_Pirates_complete_sweep_of_Astros&oldid=2933938”
Monday, August 2nd, 2021

The Neoantigen Targeted Therapies Market, 2019 2030 Report Features An Extensive Study Of The Curr

To order this detailed 320+ page report, please visit this link

Key Inclusions

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer.
  • Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
  • A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.
  • An in-depth analysis of the various patents that have been filed / granted related to neoantigens till April 2019. It includes information on key parameters, such as patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio).
  • An analysis of the various partnerships pertaining to neoantigen targeting therapies, which have been established till March 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, type of immunotherapy and the most active players.
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies.
  • Informed estimates of the existing market size and the future opportunity for neoantigen targeted therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2019-2030.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

  • Type of target disease indication
  • Bone cancer
  • Colorectal cancer
  • Gynecological cancer
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Other cancers
  • Type of neoantigens
  • Personalized neoantigens
  • Off-the-shelf neoantigens
  • Type of immunotherapy
  • Dendritic cell vaccines

Press Release: Variation 4 (Format 5)

  • DNA / RNA-based vaccines
  • Protein / peptide-based vaccines
  • TIL-based therapies
  • Route of administration
  • Intradermal
  • Intravenous
  • Subcutaneous
  • Other routes
  • Key geographical regions
  • North America
  • Europe
  • Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes.The report includes detailed transcripts of discussions held with the following experts:

  • Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
  • Ella Sorani (Vice President Research and Development, BioLineRx)
  • Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)

To request sample pages, please visit this link

Key Questions Answered

  • What are the prevalent trends related to R&D activity focused on neoantigen based therapies?
  • What are the clinical conditions for which neoantigen targeted therapies are being developed?
  • What are the key challenges faced by neoantigen-based therapy developed?
  • Who are the leading industry and non-industry players?
  • What are the key factors that are likely to influence the evolution of the neoantigen targeted therapies market?
  • What are the reasons for partnership activity among stakeholders in this industry?
  • Who are the key investors in neoantigen targeted therapies?
  • What is share of neoantigen targeted therapies in the immunotherapy market?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographies?

You may also be interested in the following titles:

  1. T-Cell Immunotherapies Market (4th Edition), 2019-2030
  2. Novel Immuno-Oncology Biomarker Testing Market, 2019-2030
  3. Companion Diagnostics Market (2nd Edition), 2019-2030

Contact Us:

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Sunday, August 1st, 2021

Ex-minister says UK Cabinet was “misled” about legality of Iraq war

Wednesday, February 3, 2010

Clare Short, the United Kingdom’s then-Secretary of State for International Development, appeared before the Iraq Inquiry yesterday, and told the panel that the Cabinet was “misled” about the Iraq War’s legality prior to the 2003 invasion. The three-hour session was held in the Queen Elizabeth II Conference Centre in London‘s City of Westminster.

Short, an outspoken critic of the war, retired from the cabinet to become an independent MP two months before the invasion. She claimed to have been “conned” into staying on despite her doubts about the war and told the inquiry that the Cabinet, of which she was a part, was not a “decision-making body”, and that Parliament was simply a “rubber stamp”.

She also claimed that Tony Blair “and his mates” had acted “on a wing and a prayer”, having “leaned on” then-Attorney General for England and Wales Lord Peter Goldsmith, pressurising him to change his mind about the invasion. She did, however, admit that she had no evidence to support these claims. Goldsmith gave a verdict that the war would be legal only shortly before the invasion, having firmly held the belief that it would not be without a further United Nations Security Council resolution.

Short was applauded as she concluded her testimony, in which she said that she was “shocked” at how a definitive statement about the legality of the war circulated only as late as March 17, 2003 — just three days before the invasion began — that this state of shock led her to be “jeered at” by other ministers. Said statement, according to Short, contained no hint that Goldsmith had previously had any doubts whatsoever.

She said any discussion of legality was stopped at the same pre-war cabinet meeting. She accused Blair of standing in the way of such discussion, and said, “Everything that’s happened since makes me know that there was deliberate blockage and there were also all sorts of secret, private meetings”, and that normal cabinet communications were “closed down” as the invasion approached. “There was never a meeting that said ‘what’s the problem, what are we trying to achieve, what are our military, diplomatic options?’ We never had that coherent discussion … never.”

I think [Goldsmith] misled the cabinet. He certainly misled me, but people let it through

Goldsmith responded to her inquiries about the lateness of this statement by saying “it takes me a long time to make my mind up”, and that he had made his decision after consulting foreign legal professionals. She said that Goldsmith’s “doubts and his changes of opinion” made her “think for the attorney general to come and say there’s unequivocal legal authority to go war was misleading.” She said that “I think he misled the cabinet. He certainly misled me, but people let it through”.

[I]f we got a Palestinian state and a UN lead on reconstruction, that will be much better

She claimed that the government, having failed to secure a required UN resolution, started the “untrue” rumour that France had vetoed it. She said that she “believed them at the time. You don’t want to disbelieve your Prime Minister in the run-up to war and you want to believe the leader of your party. You want to be loyal”.

When asked why she had not resigned earlier than she did, she said that she “was conned” by Blair’s promises of a strong role for the UN in the reconstruction of Iraq, as well as more attempts to resolve the conflict about Israel. She said that she “thought that if we got a Palestinian state and a UN lead on reconstruction, that will be much better … I took a lot of flak for it. I still think, if we had done those things, it would have been a heck of a lot better.” She says that this lack of UN involvement in the post-invasion reconstruction effort was her main reason for retiring from the government.

Short said that she “was seeing the intelligence” about Iraq at the earlier stages of preparation for an invasion, but that in late 2002 “asked for a briefing… This just didn’t come and didn’t come… it became clear there was some sort of block on communications.” Apparently, the intelligence reports she say said that “Saddam Hussein didn’t have nuclear [weapons] … [he] would if he could but he was nowhere near it. It wasn’t saying there was some new imminent threat”.

Short asserted Blair’s evidence, given to the inquiry on Friday, was “historically inaccurate”, since “[t]here was no evidence of any kind of an escalation of threats” after the September 11 terrorist attacks on the World Trade Centre. This is contrary to Blair’s claims that attitudes towards the threat Iraq posed “changed dramatically” after the attacks, and that Saddam Hussein “threatened not just the region but the world”.

We could have gone more slowly and carefully and not have had a totally destabilised and angry Iraq

She said, “We could have gone more slowly and carefully and not have had a totally destabilised and angry Iraq. The American people were misled to suggest that al-Qaeda had links to Saddam Hussein. Everybody knows that is untrue – that he had absolutely no links, no sympathy, al-Qaeda were nowhere near Iraq until after the invasion and the disorder that came from that.” Short criticised the military for not meeting the obligations laid out for them, as an occupying force, by the Geneva Convention.

Lord Boyce, the former head of the British armed forces, said in an earlier hearing that officials from the Department for International Development — Short’s department — let their opposition to the war prevent them from cooperating fully with the rest of the government immediately after the invasion. Alistair Campbell, Blair’s former spokesman, said that Short had been “difficult to handle” in the run-up to the invasion, and that there was fear that she may leak pieces of information that she did not agree with. Lord Andrew Turnbull, former Secretary of the Cabinet, however, said that these concerns were unfair, and that minority voices had been unfairly pushed to the sidelines.

Hilary Benn, who took over Short’s post after her resignation, is scheduled to give evidence before the inquiry today.

Retrieved from “https://en.wikinews.org/w/index.php?title=Ex-minister_says_UK_Cabinet_was_%22misled%22_about_legality_of_Iraq_war&oldid=4091606”